Physician profile
James Wachter
NPI 1689670697
$29,402.35
in general payments reported to CMS, 2019-2025
14 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $236 · 2021: $326 · 2022: $27K · 2023: $245 · 2024: $246 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $27,088.48 | 2019-2022 | |
| Coopervision INC. | $723.12 | 2019-2023 | Myday Contact Lens |
| Carl Zeiss Meditec USA, INC. | $294.34 | 2022-2025 | Lumera 700 |
| Allergan, INC. | $268.53 | 2021-2022 | |
| Alcon Vision LLC | $214.66 | 2019-2021 | |
| Harrow Eye, LLC | $151.21 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $147.98 | 2020 | |
| Abbvie INC. | $135.74 | 2023 | Durysta |
| Biotissue Holdings INC. | $123.00 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $74.51 | 2021-2022 | |
| Glaukos Corporation | $55.90 | 2021 | |
| Staar Surgical Company | $47.96 | 2019 | |
| Maculogix, INC. | $42.74 | 2021 | |
| Kala Pharmaceuticals, INC. | $34.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.